CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,244 enrolled
Drug / intervention
Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs +3 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05303662
NCT05303662N/ACompleted

Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an Endoscopic Retrograde Cholangiopancreatography in Four Different Countries

Marco J. Bruno·observational·Posted Mar 31, 2022·Updated Aug 8, 2025

In Brief

An observational study evaluating Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs, MDRO-testing duodenal aspirate, and 2 other interventions for Drug Resistance, Multiple, Bacterial and Cholangiopancreatography, Endoscopic Retrograde. Completed, enrolled 1,244 participants across 4 sites in 4 countries.

Detailed Summary

The duodenoscopes currently used for Endoscopic Retrograde Cholangio - and Pancreaticography (ERCP) examinations are reusable and are therefore washed and disinfected after each use. Despite this, these endoscopes sometimes remain contaminated with bacteria. Several reports of outbreaks linked to contaminated duodenoscopes have been published worldwide. Recently, the Food and Drug Administration (FDA) advised manufacturers and health care professionals to transition away from fixed endcap duodenoscopes and instead focus more on the use of duodenoscopes with disposable components or fully disposable duodenoscopes. Single-use endoscopes have been developed, but they are not yet widely used, partly because of the extra costs that these endoscopes add to the examination. A possible interim solution, is to only use these disposable endoscopes in patients who carry multi-resistant bacteria in order to prevent the spread of these bacteria. For this, it is important to know how many people who undergo an ERCP carry multi-resistant bacteria. The primary objective of this study is to measure the prevalence of multi-resistant bacteria in patients undergoing ERCP in four different countries: India, the Netherlands, Italy and the United States. In the Netherlands, some secondary outcomes will be investigated with regard to the prevalence of duodenoscope contamination, the risk of bacterial transmission via a contaminated duodenoscope and the presence of multi-resistant bacteria in the duodenum.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesIndia, Italy, Netherlands, United States

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMar 31, 2022
Enrollment StartJan 31, 2022
Primary CompletionDec 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 4.3 years ago

Interventions

Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabsother

Pooled throat/nose sample and a rectal sample is taken prior to the ERCP

MDRO-testing duodenal aspirateother

Duodenal aspirate is collected from the duodenum, diluted and undiluted. Then cultured for presence of MDRO's

Microbiome through rectal swabother

An rectal swab is collected for microbiome purposes

Microbiome testing duodenal aspirateother

Duodenal aspirate is collected from the duodenum, diluted and undiluted for microbiome analysis